Supernus Pharmaceuticals, Inc. (SUPN) — 分析摘要
Supernus Pharmaceuticals, Inc.（SUPN）的市值为2.41十亿美元，最近一年的营收同比增长了+8.6%。净利润率为-5.4%。当前市盈率为-22.0倍。
核心要点
- 营收同比变化+8.6%
- 净利润率-5.4%
- 市盈率-22.0倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，SUPN的营收增长为+8.6%，市盈率为-22.0倍。
Supernus Pharmaceuticals, Inc. (SUPN)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
营业利润率为 -15.7% — 经营亏损显著
净利润较上一期下降 185.0%。
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
778
总部
ROCKVILLE, MD
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。